arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Ginkgo Bioworks Holdings, Inc.

DNA
$8.58 ▼ -0.77 (-8.24%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
25 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ginkgo Bioworks Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $532.8M
Dividend Yield —
Revenue Growth -59.4% →
Op. Margin -290.5% ↗
ROIC -14.0% ↗
FCF / Share $-0.76 ↗
Trailing P/E —
Price / Book 1.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.16M
↓ -59.4% —
Net Income Profit after all expenses
$-46.71M
↑ +22.5% —
Operating Margin Operating profit as % of sales
-290.5%
↑ +20.7% 0th
FCF / Share Free cash flow per share
$-0.76
↑ +7.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
14
Financial Health ↓
0
Cash Quality ↑
43

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 25 quarters